Europroteome ag moneyhouse registration#
Abbott is a first-choice development partner who will ensure that the results of this collaboration are rapidly translated into products that provide a significant medical benefit. Canadian Trademarks filed by EUROPROTEOME AG, APPLICATION TRADEMARK FILING DATE CURRENT STATUS TRADEMARK OWNER WATCH DEAD : 1104321: Logo: Registration cancelled. Ulrich Traugott, chief executive officer, Europroteome said, "The extension of this collaboration underlines Europroteome's strength in cancer biomarker discovery. Ulrich Traugott Email Address Found 1 email address listing:. Click here to load this Caspio Online Database.
Europroteome ag moneyhouse license#
Abbott has an option for a royalty-bearing license to the results from the research collaboration and will be responsible for commercial assay development and worldwide sales and marketing, the release says. Chief Executive Officer Europroteome Ag Preparing Ulrichs profile View Ulrichs Email (Its Free) 5 free lookups per month. Europroteome Ag: Assignee: Application Publication: 09381266 20020150569: Diagnosis Of Epithelial Cell Abnormalities Diagnosis Of Epithelial Cell Abnormalities: 4/24. Contact us 24/7 at 80, by email at, or use the handy form provided below: Please note that you must complete all mandatory fields marked with an asterisk (). Abbott made an upfront payment to Europroteome and has provided commercial assay kits and instruments. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority to GB9705949 priority. Combinations of markers are selected for further development and integration into Abbott's instrument platforms, used widely in hospitals and clinical laboratories throughout the world. EUROPROTEOME AG Original Assignee EUROPROTEOME AG Priority date (The priority date is an assumption and is not a legal conclusion. Data are aligned with a panel of cancer markers available from Abbott Laboratories on Abbott's automated immunoassay platforms. Under the agreement signed in February 2004, Europroteome applies advanced proteomic and bioinformatic technologies to analyze serum samples from women with breast cancer. Denmarks Genmab A/S has acquired rights to 16 potential targets to treat non-steroid dependent cancers, including colon cancer, from Europroteome AG, a private German company currently in insolvency proceedings. Ciphergen Biosystems GmbH Hannah-Vogt-Str.
The extension triggers a milestone payment from Abbott to Europroteome, according to a company release. Ciphergen Biosystems AG - Freebase Die Europroteome AG ver-wendet fr die vergleichende. WINNIPEG, MANITOBA - Miraculins Inc., a biotechnology company engaged in the discovery and development of products for select cancers, announced on Thursday that it has acquired intellectual property (IP) assets of Europroteome AG, a former developer of products for the diagnostic, prognostic, and patient specific therapy of human cancers. Europroteome AG have extended their research collaboration with Abbott Laboratories for the discovery and development of novel breast cancer diagnostic tests upon successfully reaching a project milestone.
0 kommentar(er)
